stockportfolio.pro
Mirum Pharmaceuticals, Inc. (MIRM)
Healthcare · Biotechnology · NasdaqGM
Mirum Pharmaceuticals, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $19.14M | $77.06M | $186.37M | $336.89M | $521.31M |
| Gross profit | — | — | — | $64.69M | $139.34M | $255.25M | $421.07M |
| Net income | $-52.55M | $-103.27M | $-83.99M | $-135.66M | $-163.41M | $-87.94M | $-23.36M |
| Net margin | — | — | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
Source: Mirum Pharmaceuticals, Inc. SEC filings (10-K).
What growth is priced into MIRM stock?
At today's market cap of $5.98B, Mirum Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 31.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $54.87M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 7 years of Mirum Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MIRM in your portfolio →
Mirum Pharmaceuticals, Inc. financial history by metric
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals, Inc. — frequently asked questions
What is Mirum Pharmaceuticals, Inc.'s revenue?
Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $521.31M for fiscal year 2025, up 54.7% from the prior year, according to its SEC filings.
Is Mirum Pharmaceuticals, Inc. profitable?
No — MIRM reported a net loss of $-23.36M in fiscal 2025.
What is MIRM's P/E ratio?
Mirum Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Mirum Pharmaceuticals, Inc. have?
As of fiscal year 2025, MIRM carried roughly $309.80M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Mirum Pharmaceuticals, Inc.'s gross margin?
MIRM's gross margin was 80.8% in fiscal 2025 — gross profit of $421.07M on revenue of $521.31M.
What is Mirum Pharmaceuticals, Inc.'s market cap?
Mirum Pharmaceuticals, Inc. (MIRM) has a market capitalization of about $5.98B, based on the latest data in our nightly-refreshed cache.
When does Mirum Pharmaceuticals, Inc.'s fiscal year end?
MIRM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into MIRM stock?
At today's market cap of $5.98B, Mirum Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 31.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $54.87M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Mirum Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.